|By Marketwired .||
|June 16, 2014 03:20 PM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 06/16/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that management is scheduled to present an overview of the Company at the 2014 Bloom Burton & Co. Healthcare Investor Conference at the Toronto Board of Trade on June 18th, 2014 at 2:30 p.m. (Eastern time). The presentation materials will also be made available on the Trimel website at www.trimelpharmaceuticals.com.
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. Natesto, a product utilizing Trimel's licensed bioadhesive nasal gel technology, has been approved for sale in the United States by the FDA. For more information, please visit www.trimelpharmaceuticals.com.